Colorectal Cancer | Oncology Today with Dr Neil Love: Colorectal Cancer Edition

published 1 month ago by Dr Neil Love

A roundtable discussion with Drs Axel Grothey and Michael J Overman on recent developments in the treatment of colorectal cancer, including the following topics: Biomarker analysis for patients with colorectal cancer (CRC) (00:00) Effect of tumor sidedness on prognosis and response to therapy (4:28) Sequencing of systemic therapy for patients with metastatic CRC (mCRC); selection of patients for therapy with EGFR antibodies (8:51) Role of BRAF mutations and the recently FDA-approved combination of encorafenib and cetuximab for patients with mCRC with a BRAF V600E mutation (17:56) Response to BRAF-targeted therapies in patients with BRAF V600E mutations (28:45) Ongoing investigation of mechanisms of resistance to BRAF-targeted therapies (36:20) Efficacy of immune checkpoint inhibitors pembrolizumab, nivolumab and nivolumab/ipilimumab in patients with mCRC; effect of MSI status on response to immunotherapy (38:11) Effect of POLE mutations and tumor mutation burden (TMB) on response to checkpoint inhibitors; recent approval of pembrolizumab for patients with unresectable or metastatic TMB-high (≥10 mut/Mb) solid tumors (47:36) Potential role of immune checkpoint inhibitors in patients with mCRC who have microsatellite-stable disease (58:32) Integration of TAS-102 and regorafenib in the management of mCRC (1:06:26) Dosing considerations and tolerability of regorafenib; association of tumor cavitation and response to regorafenib (1:13:12) Sequencing of TAS-102 and regorafenib in mCRC (1:16:51) Response to the combination of regorafenib and nivolumab among patients with mCRC (1:22:51) Targeting HER2 in mCRC; activity and side-effect profile of trastuzumab deruxtecan (1:29:39) Novel agents and strategies under investigation for patients with mCRC (1:38:23) CME information and select publications

more episodes from Research To Practice | Oncology Videos